首页> 美国卫生研究院文献>Hospital Pharmacy >Development of Institutional Guidelines for Management of Gram-Negative Bloodstream Infections: Incorporating Local Evidence
【2h】

Development of Institutional Guidelines for Management of Gram-Negative Bloodstream Infections: Incorporating Local Evidence

机译:制定管理革兰氏阴性血流感染的机构指南:结合当地证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Appropriate empirical antimicrobial therapy is associated with improved outcomes of patients with Gram-negative bloodstream infections (BSI). >Objective: Development of evidence-based institutional management guidelines for empirical antimicrobial therapy of Gram-negative BSI. >Methods: Hospitalized adults with Gram-negative BSI in 2011-2012 at Palmetto Health hospitals in Columbia, SC, USA, were identified. Logistic regression was used to examine the association between site of infection acquisition and BSI due to Pseudomonas aeruginosa or chromosomally mediated AmpC-producing Enterobacteriaceae (CAE). Antimicrobial susceptibility rates of bloodstream isolates were stratified by site of acquisition and acute severity of illness. Retained antimicrobial regimens had predefined susceptibility rates ≥90% for noncritically ill and ≥95% for critically ill patients. >Results: Among 390 patients, health care–associated (odds ratio [OR]: 3.0, 95% confidence interval [CI]: 1.5-6.3] and hospital-acquired sites of acquisition (OR: 3.7, 95% CI: 1.6-8.4) were identified as risk factors for BSI due to P aeruginosa or CAE, compared with community-acquired BSI (referent). Based on stratified bloodstream antibiogram, ceftriaxone met predefined susceptibility criteria for community-acquired BSI in noncritically ill patients (95%). Cefepime and piperacillin-tazobactam monotherapy achieved predefined susceptibility criteria in noncritically ill (95% both) and critically ill patients with health care–associated and hospital-acquired BSI (96% and 97%, respectively) and critically ill patients with community-acquired BSI (100% both). >Conclusions: Incorporation of site of acquisition, local antimicrobial susceptibility rates, and acute severity of illness into institutional guidelines provides objective evidence-based approach for optimizing empirical antimicrobial therapy for Gram-negative BSI. The suggested methodology provides a framework for guideline development in other institutions.
机译:>背景:适当的经验性抗菌治疗与革兰氏阴性血流感染(BSI)患者的预后改善相关。 >目标:为革兰氏阴性BSI的经验性抗菌治疗制定循证机构管理指南。 >方法:确定了2011-2012年在美国南卡罗来纳州哥伦比亚的Palmetto Health医院住院的革兰阴性BSI成人。 Logistic回归用于检查铜绿假单胞菌或染色体介导的产生AmpC的肠杆菌科(CAE)引起的感染获得部位与BSI之间的关联。血源分离物的抗菌药敏感率按获取部位和疾病的严重程度进行分层。保留的抗菌药物方案对非危重病人的预定义敏感性≥90%,对危重病人的≥95%。 >结果:在390例患者中,与医疗保健相关的(赔率[OR]:3.0,95%置信区间[CI]:1.5-6.3])和医院获得的获取地点(OR:3.7,与社区获得的BSI相比,鉴定出95%CI(1.6-8.4)是铜绿假单胞菌或CAE引起的BSI的危险因素(参考)头孢曲松通过分层血流生物学谱图,符合社区对BSI在非临界状态下敏感的既定敏感性标准(95%)头孢吡肟和哌拉西林-他唑巴坦单药治疗在非重症患者(95%均)和重症患者以及医疗相关的BSI和医院获得的BSI(分别为96%和97%)和严重程度达到了预定的药敏标准社区获得性BSI的患病患者(均为100%)。>结论:将获取地点,局部抗菌药易感性和疾病的严重程度纳入机构指南,为客观的基于证据的方法提供了依据革兰氏阴性BSI的经验性抗菌疗法的优化。建议的方法为其他机构制定指南提供了框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号